Internal Server Error

TD2 - About the company

TD2 is an acquired company based in Phoenix (United States), founded in 2003. It operates as an Oncology CRO accelerating cancer drug development with integrated preclinical and clinical services. The company has 2002 active competitors, including 454 funded and 326 that have exited. Its top competitors include companies like Crown Bioscience, Antheia and Transcenta.

Company Details

Oncology CRO accelerating cancer drug development with integrated preclinical and clinical services. The company is dedicated to advancing oncology drug development through precision, expertise, and efficiency. It offers strategic solutions to accelerate the path from scientific discoveries to patient therapies. The company's ecosystem connects preclinical, clinical, and regulatory phases, prioritizing scientific innovation and patient outcomes. Services include study design, patient identification, site management, biostatistics, data management, pharmacovigilance, and medical monitoring. It also provides regulatory support, including program management, protocol design, and submission filings. Preclinical services encompass model systems, bioanalytical services, and in vivo/in vitro characterization. Flow cytometry services offer analysis for preclinical and clinical studies. The company fosters collaboration, ensuring clear communication and tailored guidance. Its multidisciplinary team brings insights into oncology development, supporting programs across diverse therapeutic modalities like targeted therapies, immuno-oncology, antibody-drug conjugates, and radiopharmaceuticals.
Website
td2inc.com
Registered Address
Scottsdale, Arizona
Key Metrics
Founded Year
2003
Location
Phoenix, United States
Stage
Acquired
Ranked
Employee Count
120 as on Aug 31, 2026
Similar Companies
Exit Details
Acquired by RCT (Jun 04, 2020)

TD2's acquisition details

TD2 got acquired by RCT on Jun 04, 2020.
Click here to take a look at TD2's acquisition in detail
Sign up to download TD2's company profile

TD2's funding and investors

TD2 has not raised any funding rounds yet.

TD2's founders and board of directors

Founder? Claim Profile

TD2's employee count trend

TD2 has 120 employees as of Aug 26. Here is TD2's employee count trend over the years:
Employee count trend for TD2
lockUncover TD2's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

TD2's Competitors and alternates

Top competitors of TD2 include Crown Bioscience, Antheia and Transcenta. Here is the list of Top 10 competitors of TD2, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Crown Bioscience
Crown Bioscience
2006, Santa Clara (United States), Acquired
Developer of drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases)
$85.9M
68/100
2nd
Logo for Antheia
Antheia
2013, Palo Alto (United States), Series C
Genetically engineered yeast cells to produce medicinal products
$176M
67/100
3rd
Logo for Transcenta
Transcenta
2019, Suzhou (China), Public
Developer of antibody-based therapeutics
$205M
66/100
4th
Logo for Akeso
Akeso
2012, Zhongshan (China), Public
Developer of antibody drug conjugates for the treatment of broad spectrum diseases
$195M
65/100
5th
Logo for Korro Bio
Korro Bio
2018, Cambridge (United States), Public
Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases
$4M
64/100
6th
Logo for Fermentalg
Fermentalg
2005, Libourne (France), Public
Innovating with algae for sustainable solutions in nutrition and environmental impact
$30.3M
63/100
7th
Logo for Microban
Microban
1994, Huntersville (United States), Acquired
Antimicrobial and odor control technologies for durable product protection and freshness
$64.6M
63/100
8th
Logo for LifeMine Therapeutics
LifeMine Therapeutics
2016, Watertown (United States), Series E
Developer of novel drugs from fungi via genome mining and recombinant overexpression
$563M
63/100
9th
Logo for Dewpoint Therapeutics
Dewpoint Therapeutics
2018, Boston (United States), Series D
Developer of small molecule based therapeutics
$364M
62/100
10th
Logo for One Biosciences
One Biosciences
2020, Paris (France), Series A
Developer of single-cell therapeutics solutions to treat multiple health disorders
$22.4M
62/100
471st
Logo for TD2
TD2
2003, Phoenix (United States), Acquired
Oncology CRO accelerating cancer drug development with integrated preclinical and clinical services
-
-
34/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on TD2's competitors? Click here to see the top ones

TD2's Investments and acquisitions

TD2 has made no investments or acquisitions yet.

Reports related to TD2

Here is the latest report on TD2's sector:

News related to TD2

lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about TD2

Explore our recently published companies
  • Solar - Indore based, 1994 founded, Unfunded company
  • Bina Punjani - India based, 2011 founded, Unfunded company
  • Aviator - India based, Unfunded company
  • Admit Beacon - India based, 2021 founded, Unfunded company
  • Origin Itfs - Chennai based, 1993 founded, Unfunded company
  • 1Win - India based, 2026 founded, Unfunded company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford